Dieter Zopf

USPTO Granted Patents = 10 (Patent Applications = 2)

EPO Patents = 2 (Patent Applications = 4)

Average Co-Inventor Count = 6.1

ph-index = 4

Forward Citations = 52(Granted Patents)

Company Filing History:

6 out of 192

Bayer Schering Pharma Ag

patents

1 out of 1

Schring Aktiengesellschaft

patent

1 out of 1,384

Schering Aktiengesellschaft

patents

4. 1 out of 12,160

Bayer Aktiengesellschaft

Years Active: 2005-2024

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11951166 - Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer (2024-04-09),

2. 11517622 - Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer (2022-12-06),

3. 8003787 - Sulphoximine-substituted quinoline and quinazoline derivatives as kinase inhibitors (2011-08-23),

4. 7977325 - 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents (2011-07-12),

5. 7741333 - Quinazoline derivatives, their preparation, their use, and medicaments comprising them (2010-06-22),

6. 7601748 - Anti-androgenic pyrrolidines with tumor-inhibiting action (2009-10-13),

7. 7598263 - Cyanoquinoline derivatives, their preparation, their use, and medicaments comprising them (2009-10-06),

8. 7361645 - Androgenic 7-substituted 11-halogen steroids (2008-04-22),

9. 7138421 - Anti-androgenic pyrrolidines with tumor-inhibiting action (2006-11-21),

10. 6861432 - Piperazine derivatives that destabilize androgen receptors (2005-03-01),

Title: Dieter Zopf: Pioneering Innovator in the Field of Pharmaceuticals

Introduction:

Dieter Zopf, a visionary inventor based in Berlin, Germany, is renowned for his unwavering commitment to innovation and excellence. With a portfolio of 10 patents to his name, his groundbreaking work has significantly impacted the world of pharmaceuticals and cancer treatment.

Latest Patents:

Dieter Zopf's latest patents showcase his dedication to advancing cancer treatments. One such patent involves the combination of regorafenib and PD-1/PD-L1(2) inhibitors for the treatment of hyperproliferative disorders like cancer in humans and other mammals. This innovative approach holds great promise for improving patient outcomes and transforming the field of oncology.

Career Highlights:

Throughout his illustrious career, Dieter Zopf has held key positions at renowned pharmaceutical companies such as Bayer Schering Pharma AG and Schering Aktiengesellschaft. His contributions to drug development and research have earned him a reputation as a trailblazer in the industry, with his work continuing to shape the future of healthcare.

Collaborations:

Dieter Zopf has collaborated with esteemed colleagues in the field, including Wolfgang Schwede and Arwed Cleve. Together, they have brought forth innovative solutions that have pushed the boundaries of pharmaceutical science and revolutionized cancer treatment methodologies.

Conclusion:

In conclusion, Dieter Zopf's remarkable journey as an inventor underscores his passion for pushing the boundaries of innovation in the pharmaceutical industry. His relentless pursuit of excellence and his groundbreaking inventions stand as a testament to his enduring legacy as a pioneer in the field. Dieter Zopf's work not only inspires current inventors but also sets a high standard for future generations looking to make a meaningful impact on global healthcare.

This text is generated by artificial intelligence and may not be accurate.